AUR103

AUR103 is a novel first-in-class oral small molecule inhibitor of CD47 developed for the treatment of various malignancies. By binding to CD47 expressed on tumor cells, it blocks the interaction between CD47 and its ligand SIRPα on phagocytic cells. This inhibition disrupts the "don't eat me" signal that normally protects tumor cells from being engulfed by macrophages and other immune cells, thereby promoting phagocytosis and anti-tumor immune responses[1][3][4]. Preclinical studies indicate that AUR103 does not cause hemotoxicity—a common issue with some anti-CD47 therapies[6]. The drug is currently in Phase I clinical trials as monotherapy for advanced solid tumors and in combination with azacitidine for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), as well as with rituximab for non-Hodgkin's lymphoma (NHL)[2][4].